GCM
FULC icon

Graham Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Graham Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$328K Sell
42,741
-5,723
-12% -$53.1K 0.01% 785
2025
Q4 		$548K Buy
48,464
+17,978
+59% +$183K 0.01% 597
2025
Q3 		$280K Buy
30,486
+18,434
+153% +$133K ﹤0.01% 893
2025
Q2 		$82.9K Sell
12,052
-154,191
-93% -$825K ﹤0.01% 1222
2025
Q1 		$479K Buy
166,243
+21,301
+15% +$78.2K 0.01% 832
2024
Q4 		$681K Buy
144,942
+53,726
+59% +$198K 0.01% 620
2024
Q3 		$326K Buy
+91,216
New +$677K 0.01% 754
2023
Q4 		– Sell
-11,845
Closed -$52.6K – 1109
2023
Q3 		$52.6K Sell
11,845
-20,103
-63% -$87.9K ﹤0.01% 964
2023
Q2 		$105K Sell
31,948
-115,031
-78% -$338K ﹤0.01% 885
2023
Q1 		$419K Buy
146,979
+125,626
+588% +$1.13M 0.01% 793
2022
Q4 		$155K Buy
+21,353
New +$139K ﹤0.01% 983

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Graham Capital Management's FULC Position: Q1 2026 in Review

Graham Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 12% in Q1 2026, selling an estimated $53.1K and leaving 42,741 shares worth $328K. The position accounts for 0.01% of the portfolio, ranked #785.

Graham Capital Management first reported a position in FULC in Q4 2022 and has held it in 11 quarters since. The position peaked at $681K in Q4 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Graham Capital Management held 42,741 shares of Fulcrum Therapeutics worth $328K as of Q1 2026.
  • Graham Capital Management sold 5,723 Fulcrum Therapeutics shares in Q1 2026, an estimated $53.1K.
  • Fulcrum Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #785 holding.
  • Graham Capital Management first reported a position in Fulcrum Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • Graham Capital Management's Fulcrum Therapeutics position peaked at $681K in Q4 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.